DK2944646T3 - Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin - Google Patents

Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin Download PDF

Info

Publication number
DK2944646T3
DK2944646T3 DK15161013.6T DK15161013T DK2944646T3 DK 2944646 T3 DK2944646 T3 DK 2944646T3 DK 15161013 T DK15161013 T DK 15161013T DK 2944646 T3 DK2944646 T3 DK 2944646T3
Authority
DK
Denmark
Prior art keywords
aza
cytosine
oligonucleotide analogs
analogs incorporating
incorporating
Prior art date
Application number
DK15161013.6T
Other languages
English (en)
Inventor
Pasit Phiasivongsa
Sanjeev Redkar
Original Assignee
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37894870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2944646(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Pharmaceuticals Inc filed Critical Astex Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2944646T3 publication Critical patent/DK2944646T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15161013.6T 2005-09-29 2006-09-25 Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin DK2944646T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/241,799 US7700567B2 (en) 2005-09-29 2005-09-29 Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP06804123.5A EP1943264B1 (en) 2005-09-29 2006-09-25 Oligonucleotide analogues incorporating 5-aza-cytosine therein

Publications (1)

Publication Number Publication Date
DK2944646T3 true DK2944646T3 (da) 2020-04-06

Family

ID=37894870

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15161013.6T DK2944646T3 (da) 2005-09-29 2006-09-25 Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin
DK06804123.5T DK1943264T3 (da) 2005-09-29 2006-09-25 Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin deri

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06804123.5T DK1943264T3 (da) 2005-09-29 2006-09-25 Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin deri

Country Status (22)

Country Link
US (7) US7700567B2 (da)
EP (2) EP2944646B1 (da)
JP (1) JP5030958B2 (da)
KR (2) KR101478369B1 (da)
CN (1) CN101282986B (da)
AU (1) AU2006297375C1 (da)
CA (2) CA2623090C (da)
CY (1) CY1116876T1 (da)
DK (2) DK2944646T3 (da)
ES (2) ES2550256T3 (da)
HU (1) HUE025782T2 (da)
IL (2) IL190248A (da)
MY (1) MY145619A (da)
NO (1) NO344764B1 (da)
NZ (2) NZ597432A (da)
PH (1) PH12012502290A1 (da)
PL (1) PL1943264T3 (da)
PT (1) PT1943264E (da)
SG (2) SG10201400978PA (da)
SI (1) SI1943264T1 (da)
WO (1) WO2007041071A2 (da)
ZA (1) ZA200803522B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
EP2176279A4 (en) * 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
WO2009105258A1 (en) * 2008-02-22 2009-08-27 Nektar Therapeutics Al, Corporation Oligomer conjugates of heteropentacyclic nucleosides
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
US20150038548A1 (en) * 2012-07-09 2015-02-05 Metheor Therapeutics Corporation Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP2914254B1 (en) * 2012-10-30 2020-01-08 MEI Pharma, Inc. Combination therapies to treat chemoresistant cancers
DK2961388T3 (da) * 2013-03-01 2019-07-08 Astex Pharmaceuticals Inc Kombinationer af lægemidler
CN103305604B (zh) * 2013-05-09 2015-05-06 宁波大学 可用于检测与冠心病相关的cdkn2b基因启动子区甲基化程度的试剂盒及其应用
WO2014204856A1 (en) * 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP2018528968A (ja) 2015-09-17 2018-10-04 ユニバーシティ オブ マサチューセッツ Ｆｍｒ１発現を調節するための組成物および方法
WO2017183215A1 (ja) * 2016-04-21 2017-10-26 大原薬品工業株式会社 ５－アザシチジン類の糖部シリルエーテル誘導体
US10227374B2 (en) * 2016-04-21 2019-03-12 Ohara Pharmaceutical Co., Ltd. Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety
JP6162349B1 (ja) * 2016-04-21 2017-07-12 大原薬品工業株式会社 ５−アザシチジン類の糖部シリルエーテル誘導体
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
CN106929476A (zh) * 2017-03-29 2017-07-07 大连理工大学 一种去甲基化试剂在人白血病细胞中的应用
EP3634972A2 (en) 2017-07-11 2020-04-15 Teva Czech Industries s.r.o. Improved processes for the preparation of guadecitabine and intermediates thereof
CN111182908A (zh) 2017-08-03 2020-05-19 大塚制药株式会社 药物化合物及其纯化方法
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
CN112367971A (zh) 2018-06-11 2021-02-12 加利福尼亚大学董事会 用以治疗眼睛疾病的脱甲基化
CN109232692A (zh) * 2018-09-14 2019-01-18 中国医学科学院放射医学研究所 一种脱氧胞苷类有机合成中间体及其制备方法
US20220033387A1 (en) * 2018-09-25 2022-02-03 The Usa, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
US12448624B2 (en) 2018-10-19 2025-10-21 Interoligo Corporation Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
CN112888700B (zh) * 2018-10-19 2025-03-04 因特欧力多公司 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
WO2021060341A1 (ja) * 2019-09-26 2021-04-01 大原薬品工業株式会社 Ｄｎｍｔ阻害剤の用途
JP7606109B2 (ja) 2020-03-13 2024-12-25 セントラル硝子株式会社 ドライエッチング方法、半導体デバイスの製造方法及びドライエッチングガス組成物
CN113425293B (zh) * 2021-06-29 2022-10-21 上海交通大学医学院附属新华医院 一种听觉失认障碍评估系统及方法

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2105468A1 (en) 1970-04-23 1971-11-18 Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen 1-glycosyl-5-aza-cytosines prepn
US5157120A (en) * 1980-09-16 1992-10-20 Syntex (U.S.A.) Inc. Guanine derivatives
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
JPS61161204A (ja) * 1985-01-10 1986-07-21 レプリゲン　コーポレーシヨン 抗植物ウイルス剤
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US4740560A (en) * 1986-04-17 1988-04-26 The Dow Chemical Company ABS resins and process for making them
GB8612826D0 (en) 1986-05-27 1986-07-02 Boots Co Plc Insecticidal compositions
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE3712786A1 (de) 1987-04-15 1988-11-03 Merck Patent Gmbh Verfahren und mittel zur bestimmung von nucleinsaeuren
CS269077B1 (cs) 1987-10-01 1990-04-11 Piskala Alois Způsob přípravy 5-azacytosinů
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US4904770A (en) 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5324831A (en) * 1988-04-06 1994-06-28 The United States Of America As Represented By The Secretary Of Health And Human Services Phosphoramidite reagent for chemical synthesis of modified DNA
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
CA2111571C (en) 1991-07-05 2005-08-23 Reid W. Von Borstel Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
IL103311A0 (en) 1991-10-07 1993-03-15 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
JPH05219974A (ja) 1992-02-13 1993-08-31 Mitsui Petrochem Ind Ltd トロパンアルカロイドの製造方法
JPH05246891A (ja) 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
KR100392057B1 (ko) 1993-11-30 2003-10-30 맥길 유니버시티 세포의 CpG 디뉴클레오티드 내의 시토신의 메틸화를 감소하는 방법
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
WO1996036693A1 (en) 1995-05-19 1996-11-21 Phytera, Inc. Manipulation of plant cell and tissue cultures
JPH11507047A (ja) 1995-06-06 1999-06-22 ケース ウエスターン リザーブ ユニバーシティ ヒト間葉幹細胞の筋原性分化
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
EP0843555B1 (en) 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomal oligonucleotide compositions
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
RU98113785A (ru) 1995-12-22 2000-06-10 Ист Каролина Юниверсити (US) Агент и способ лечения заболеваний, связанных с чрезмерной экспрессией цитидиндезаминазы или дезоксицитидинзаминазы
CN1268140A (zh) 1996-10-16 2000-09-27 Icn药品公司 单环l－核苷、类似物及其应用
US6423692B2 (en) 1997-04-24 2002-07-23 Dana-Farber Cancer Institute, Inc. Method of enhancing the effectiveness of DCK phosphorylated molecules
DE69829984D1 (de) 1997-08-29 2005-06-02 Univ California Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
WO2000023112A1 (en) 1998-10-19 2000-04-27 Methylgene, Inc. Modulation of gene expression by combination therapy
DK2112166T3 (da) 1998-12-23 2019-02-04 Pfizer Humane monoklonale antistoffer til CTLA-4
WO2000040269A2 (en) 1999-01-05 2000-07-13 Lee Clarence C Pharmaceutical compositions for treatment of diseased tissues
WO2000062075A1 (en) 1999-04-13 2000-10-19 Rutgers, The State University Of New Jersey Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
DE19935303A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
JP2001163776A (ja) 1999-09-30 2001-06-19 Nisshin Oil Mills Ltd:The 安定化された液剤
AU785115B2 (en) 1999-10-18 2006-09-21 Emory University TMS1 compositions and methods of use
US20020115117A1 (en) 2000-03-15 2002-08-22 Shuk-Mei Ho ERbeta-mediated gene expression
EP1315970B1 (en) 2000-09-08 2010-03-17 Seoul National University Industry Foundation Nucleic acid sequence and protein involved in cellular senescence
US6858935B1 (en) 2000-12-07 2005-02-22 Cadence Design Systems, Inc. Simulating euclidean wiring directions using manhattan and diagonal directional wires
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
JP2002223753A (ja) 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
ES2252461T3 (es) 2001-02-05 2006-05-16 Innoventus Project Ab Glicoproteina rica en histidina (hrgp) para la inhibicion de la angiogenesis.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US20060194275A1 (en) 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP2283845A1 (en) 2001-04-26 2011-02-16 pSivida Inc. Sustained release drug delivery system containing codrugs
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
JP2004536596A (ja) 2001-06-08 2004-12-09 ユー．エス． ジェノミクス， インコーポレイテッド メチル化状態に基づいて核酸を分析するための方法および生成物
JP2002370939A (ja) 2001-06-12 2002-12-24 Taisho Pharmaceut Co Ltd 育毛剤
WO2002102307A2 (en) * 2001-06-15 2002-12-27 Ribapharm Nucleoside vaccine adjuvants
US20030045497A1 (en) 2001-07-27 2003-03-06 Geneinvent Bbl Ab Methylation resistant vectors
SE518759C2 (sv) 2001-07-27 2002-11-19 Geneinvent Bbl Ab Vektorer motståndskraftiga mot metylering
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
ES2334774T3 (es) 2001-09-05 2010-03-16 Chemgenex Pharmaceuticals Limited Tratamiento de la leucemia mielogena cronica, resistente o intoleranteal sti571, que consiste en homoharrigtonina sola o combinada con otros agentes.
IN2014DN10834A (da) 2001-09-17 2015-09-04 Psivida Inc
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
CN100441176C (zh) 2001-09-24 2008-12-10 杰西·L·S·奥 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
WO2003031932A2 (en) 2001-10-05 2003-04-17 Case Western Reserve University Methods and compositions for detecting colon cancers
KR100616369B1 (ko) 2001-11-08 2006-08-28 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 벼의 트랜스포존 유전자
MXPA04004882A (es) 2001-11-23 2005-04-11 Chugai Pharmaceutical Co Ltd Metodo para la identificacion de enzimas que tienen como objetivo tumores.
RU2313365C2 (ru) 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
US20050080027A1 (en) 2001-11-30 2005-04-14 Markus Horer Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
GB0201498D0 (en) 2002-01-23 2002-03-13 Biotech Res Ventures Pte Ltd Materials and methods for treating cancer
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
CA2373890C (en) * 2002-02-28 2006-11-28 Portes Patio Resiver Inc Stress distribution hole for window sash
WO2003076660A1 (en) 2002-03-13 2003-09-18 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
JP2003310293A (ja) 2002-04-26 2003-11-05 Mitsui Chemicals Inc ヌクレオシド化合物の製造法
DK1507556T3 (da) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin-derivat-bærerkonjugater
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003251483A1 (en) 2002-06-05 2003-12-22 Case Western Reserve University Methods and compositions for detecting cancers
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
WO2005115450A1 (en) 2004-05-26 2005-12-08 Biovaxim Limited Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
JP2008518902A (ja) 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
EP1833506B1 (en) 2004-12-29 2015-08-26 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US20070105792A1 (en) 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
CN101361718B (zh) 2008-09-26 2013-08-28 深圳万乐药业有限公司 稳定的地西他滨冻干制剂的制备方法
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
KR20140029446A (ko) 2011-04-15 2014-03-10 컴퓨젠 엘티디. 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
EP2811984B1 (en) 2012-02-06 2015-08-26 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
DK2961388T3 (da) 2013-03-01 2019-07-08 Astex Pharmaceuticals Inc Kombinationer af lægemidler
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions

Also Published As

Publication number Publication date
NZ566617A (en) 2012-02-24
WO2007041071A3 (en) 2007-09-20
IL190248A0 (en) 2008-11-03
KR20080059612A (ko) 2008-06-30
CN101282986B (zh) 2012-06-27
US9480698B2 (en) 2016-11-01
AU2006297375A1 (en) 2007-04-12
US8461123B2 (en) 2013-06-11
US20130236536A1 (en) 2013-09-12
US10456415B2 (en) 2019-10-29
US20170035794A1 (en) 2017-02-09
KR101478369B1 (ko) 2015-01-02
IL218618A0 (en) 2012-04-30
US10933079B2 (en) 2021-03-02
PL1943264T3 (pl) 2015-12-31
HK1120518A1 (en) 2009-04-03
AU2006297375B2 (en) 2012-06-07
JP5030958B2 (ja) 2012-09-19
US20220000900A1 (en) 2022-01-06
HUE025782T2 (en) 2016-05-30
US20200215092A1 (en) 2020-07-09
EP2944646B1 (en) 2020-01-08
PH12012502290A1 (en) 2015-02-25
US20100215729A1 (en) 2010-08-26
NO344764B1 (no) 2020-04-20
WO2007041071A2 (en) 2007-04-12
CN101282986A (zh) 2008-10-08
KR20130137725A (ko) 2013-12-17
NZ597432A (en) 2013-05-31
IL218618A (en) 2013-12-31
IL190248A (en) 2012-08-30
ES2550256T3 (es) 2015-11-05
CA2623090A1 (en) 2007-04-12
US20070072796A1 (en) 2007-03-29
CA2895866A1 (en) 2007-04-12
CA2895866C (en) 2018-09-04
ES2782998T3 (es) 2020-09-16
SI1943264T1 (sl) 2016-01-29
US9358248B2 (en) 2016-06-07
MY145619A (en) 2012-03-15
SG166112A1 (en) 2010-11-29
US7700567B2 (en) 2010-04-20
CY1116876T1 (el) 2017-04-05
DK1943264T3 (da) 2015-10-26
EP1943264A4 (en) 2013-08-14
EP1943264B1 (en) 2015-07-29
NO20082050L (no) 2008-06-27
CA2623090C (en) 2015-11-10
PT1943264E (pt) 2015-11-02
JP2009509531A (ja) 2009-03-12
ZA200803522B (en) 2009-07-29
AU2006297375C1 (en) 2016-06-16
EP2944646A1 (en) 2015-11-18
SG10201400978PA (en) 2014-08-28
EP1943264A2 (en) 2008-07-16
US20160130296A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
DK2944646T3 (da) Oligonukleotidanaloger, der inkorporerer 5-aza-cytosin
NL300935I2 (nl) guselkumab.
ATE477257T1 (de) Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
NL1031385A1 (nl) Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
CR10353A (es) Nuevos compuestos.
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
DK3275965T3 (da) Sammensætninger, der omfatter en fluorolefin
NO20051199D0 (no) Rorhandteringsutstyr.
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
DK1883469T3 (da) Katalysatorfremstilling
DK1907574T3 (da) Oligonukleotider
NO20053362L (no) Syklofuge.
EP1960358A4 (en) ANTINEOPLASTIC COMPOUNDS
NL1032046A1 (nl) Prostaglandinederivaten.
EP1888082A4 (en) MOTILIDVERBINDUNGEN
EP1880856A4 (en) INKJET RECORDING APPARATUS
ITMI20050051A1 (it) Fotodiodio organico di poli-9,9-diottil-fluorene
NL1030303A1 (nl) Tweewieler.
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano
ITRN20050016U1 (it) Struttura combinata.